2162 — Keymed Biosciences Income Statement
0.000.00%
Last trade - 00:00- HK$12.10bn
- HK$10.61bn
- CNY428.12m
Annual income statement for Keymed Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 110 | 100 | 354 | 428 |
| Cost of Revenue | |||||
| Gross Profit | — | 93.1 | 97.5 | 317 | 416 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 805 | 3,991 | 386 | 688 | 913 |
| Operating Profit | -805 | -3,881 | -285 | -334 | -485 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -819 | -3,893 | -304 | -356 | -509 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -819 | -3,893 | -304 | -358 | -515 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -819 | -3,887 | -308 | -359 | -515 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -819 | -3,887 | -308 | -359 | -515 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.02 | -24.1 | -1.18 | -1.37 | -1.97 |
| Dividends per Share |